GW Pharmaceuticals Crashed 17% in May


Pixabay / PIX1861 / CC0 Public Domain

The threat of increasing competition for GW Pharmaceuticals’ promising epilepsy drug took a toll on investors’ confidence last month.

Following comments from a competitor’s CEO that suggest competition for the company’s epilepsy drug is in the works, shares in GW Pharmaceuticals (NASDAQ:GWPH) tumbled by 17.2% in May, according to S&P Global Market Intelligence.

GW Pharmaceuticals has made a name for itself by pioneering research into the use of marijuana-derived cannabinoids as medicine.

View Original Article Here

Repost is the designation for articles collected from the Internet whose content may interest our readers. These articles are not written by our staff and they do not necessarily reflect our views.

Related posts